

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/234102 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2022/062311

(22) International Filing Date:
06 May 2022 (06.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/201,634 06 May 2021 (06.05.2021) US

(71) Applicant: AMGEN RESEARCH (MUNICH) GMBH
[DE/DE]; Staffelseestrasse 2, 81477 Munich (DE).

(72) Inventors: PANZER, Marc; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). HONER, Jonas; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). DEISTING, Wibke; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). RAUM, Tobias; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). GAEDTKE, Lars; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). RAU, Doris; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE). WINKEL, Lisa; c/o Amgen Research (Munich) GmbH, Staffelseestrasse 2, 81477 Munich (DE).

(74) Agent: WEINZIERL, Gerhard et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/234102 A1

(54) Title: CD20 AND CD22 TARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES

(57) Abstract: The present invention provides CD20 and CD22 targeting antigen-binding molecules characterized by comprising a first and a second domain, binding to CD20 and CD22, respectively, a third domain binding to an extracellular epitope of the human and the *Macaca* CD3e chain and optionally a fourth domain, which is a Fc modality. Moreover, the invention provides a polynucleotide, encoding the antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the antigen-binding molecule and a pharmaceutical composition comprising the same.